Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: Evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant alleles

Tropical Medicine and International Health

Volumn 20, Issue 4, 2015, Pages 510-517

  Warsame, Marian ^a   Hassan, Abdillahi Mohamed ^a   Barrette, Amy ^a   Jibril, Ali Mohamed ^b   Elmi, Husein Haji ^c   Arale, Abdulkadir Mohamed ^d   Mohammady, Hanan El ^e   Nada, Rania A ^e   Amran, Jamal Ghilan Hefzullah ^a   Muse, Abdikarim ^a   Yusuf, Fahmi Essa ^a   Omar, Abdiqani Sheikh ^d  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b INTERSOS   (Somalia)

^c Jamame   (Somalia)

^d Ministry of Health   (Somalia)

^e US Naval Medical Research Unit No 3 Egypt   (Egypt)

Author keywords

Artemisinin based combination therapy; Drug resistance; Malaria; Plasmodium falciparum; Somalia

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; MOLECULAR MARKER; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE-ARTESUNATE;

ALLELE; DRUG RESISTANCE; HEALTH POLICY; MALARIA; MUTATION; PARASITOLOGY; PROTOZOAN; SPATIOTEMPORAL ANALYSIS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLELE; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHILD; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; HEALTH CARE POLICY; HUMAN; IN VIVO STUDY; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDY; SINGLE DRUG DOSE; SOMALIA; STANDARD; AGE; BACTERIAL GENE; ENZYMOLOGY; EVALUATION STUDY; GENETICS; MALARIA, FALCIPARUM; MIDDLE AGED; MULTIDRUG RESISTANCE; MUTATION; PARASITOLOGY; PRESCHOOL CHILD; TREATMENT FAILURE; YOUNG ADULT;

SOMALIA;

PLASMODIUM FALCIPARUM;

ADOLESCENT; ADULT; AGE FACTORS; ALLELES; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DIHYDROPTEROATE SYNTHASE; DRUG RESISTANCE, MULTIPLE; FEMALE; GENES, BACTERIAL; HEALTH POLICY; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MUTATION; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SOMALIA; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT FAILURE; YOUNG ADULT;

EID: 84924240141     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12458     Document Type: Article

References (33)

1. WHO. World Malaria Report 2013. World Health Organization: Geneva, 2013.
2. Noor AM, Clements AC, Gething PW et al. Spatial prediction of Plasmodium falciparum prevalence in Somalia. Malaria J 2008: 7: 159.
3. Warsame M, Atta H, Klena JD et al. Efficacy of monotherapies and artesunate-based combination therapies in children with uncomplicated malaria in Somalia. Acta Trop 2009: 109: 146-151.
4. WHO. Global Report on Antimalarial Efficacy and Drug Resistance: 2000-2010. World Health Organization: Geneva, 2010.
5. WHO. Guidelines for the Treatment of Malaria (2nd edn), World Health Organization: Geneva, 2010.
6. WHO. Updated WHO Policy Recommendation: Intermittent Preventive Treatment of Malaria in Pregnancy Using Sulfadoxine-Pyrimethamine (IPTp-SP). World Health Organization: Geneva, 2012.
7. WHO. Status Report on Artemisinin Resistance. http://www.who.int/malaria/publications/atoz/status_rep_artemisinin_resistance:sep2014.pdf. World Health Organization: Geneva, 2014. [01 January 2015]
8. Roper C, Pearce R, Bredenkamp B et al. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 2003: 361: 1174-1181.
9. Plowe CV. Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Curr Top Microbiol Immunol 2005: 295: 55-79.
10. Wernsdorfer WH, Noedl H. Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Curr Opin Infect Dis 2003: 16: 553-558.
11. Kublin JG, Dzinjalamala FK, Kamwendo DD et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002: 185: 380-388.
12. Mombo-Ngoma G, Oyakhirome S, Ord R et al. High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children. Malaria J 2011: 10: 123.
13. Mugittu K, Ndejembi M, Malisa A et al. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am J Trop Med Hyg 2004: 71: 696-702.
14. Basco LK, Tahar R, Keundjian A, Ringwald P. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. J Infect Dis 2000: 182: 624-628.
15. Nzila AM, Nduati E, Mberu EK et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis 2000: 181: 2023-2028.
16. WHO. Methods for Surveillance of Antimalarial Drug Efficacy. World Health Organization: Geneva, 2009.
17. WHO. Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations. World Health Organization: Geneva, 2008.
18. Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg 1996: 55: 209-213.
19. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999: 41: 95-98.
20. Omar SA, Adagu IS, Warhurst DC. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 2001: 95: 315-319.
21. Staedke SG, Sendagire H, Lamola S, Kamya MR, Dorsey G, Rosenthal PJ. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Tropical Med Int Health 2004: 9: 624-629.
22. Barnes KI, Watkins WM, White NJ. Antimalarial dosing regimens and drug resistance. Trends Parasitol 2008: 24: 127-134.
23. Djimde AA, Doumbo OK, Traore O et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 2003: 69: 558-563.
24. Happi CT, Gbotosho GO, Folarin OA et al. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop 2005: 95: 183-193.
25. Raman J, Mauff K, Muianga P, Mussa A, Maharaj R, Barnes KI. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS ONE 2011: 6: e25992.
26. Allen EN, Little F, Camba T et al. Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial. Malaria J 2009: 8: 141.
27. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004: 305: 1124.
28. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis 2011: 53: 224-230.
29. Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald M, Mwapasa V. Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J Infect Dis 2011: 203: 464-472.
30. Menendez C, Bardaji A, Sigauque B et al. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS ONE 2008: 3: e1934.
31. Menendez C, Bardaji A, Sigauque B et al. Malaria prevention with IPTp during pregnancy reduces neonatal mortality. PLoS ONE 2010: 5: e9438.
32. Mockenhaupt FP, Bedu-Addo G, Eggelte TA et al. Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana. J Infect Dis 2008: 198: 1545-1549.
33. Wilson NO, Ceesay FK, Obed SA et al. Intermittent preventive treatment with sulfadoxine-pyrimethamine against malaria and anemia in pregnant women. Am J Trop Med Hyg 2011: 85: 12-21.